Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma

To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen. Patients with locally-advanced or metastatic pancreatic adenocarcinoma from French and Canadian centers, who were treated with the first-line FOLFIRINOX regimen (FFX L1), followed by gemcitabine mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilabert, Marine, Chanez, Brice, Rho, Young Soo, Giovanini, Marc, Turrini, Olivier, Batist, Gerald, Kavan, Petr, Raoul, Jean Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406057/
https://www.ncbi.nlm.nih.gov/pubmed/28422841
http://dx.doi.org/10.1097/MD.0000000000006544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406057/
https://www.ncbi.nlm.nih.gov/pubmed/28422841
http://dx.doi.org/10.1097/MD.0000000000006544

Ejemplares similares